Regeneron's Delivery Isn't Matching The Hype

The problem with sky-high expectations is that you have to meet them. Regeneron Pharmaceuticals Inc. and its partner Sanofi on

Monday released trial data for their drug Dupixent in treating severe asthma that, while likely good enough to net an FDA approval, fell short enough of very high hopes to send Regeneron shares down 5 percent.

Imperfect data on a pipeline darling is bad news for any company.

Back to news